S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Editas Medicine Price Target, Predictions & Analyst Ratings

-0.93 (-2.79%)
(As of 11/26/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
830,601 shs
Average Volume
1.89 million shs
Market Capitalization
$2.21 billion
P/E Ratio
Dividend Yield

Editas Medicine (NASDAQ:EDIT) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Based on 17 Analyst Ratings

Analyst Price Target Consensus

76.91% Upside

High PT$86.00
Average PT$57.27
Low PT$20.00
11/28/20 to 11/28/21
1 Month Ago
10/29/20 to 10/29/21
3 Months Ago
8/30/20 to 8/30/21
1 Year Ago
11/29/19 to 11/28/20
Consensus Rating
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
7 Buy rating(s)
3 Buy rating(s)
5 Hold rating(s)
5 Hold rating(s)
3 Hold rating(s)
4 Hold rating(s)
3 Sell rating(s)
3 Sell rating(s)
4 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$57.27$54.88$54.86$38.67
Price Target Upside76.91% Upside17.21% Upside16.54% Upside32.53% Upside
Get Editas Medicine Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.

Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Editas Medicine (NASDAQ:EDIT) vs. Its Competitors

TypeEditas MedicineMedical CompaniesS&P 500
Consensus Rating Score
Consensus RatingHoldBuyBuy
Price Target Upside76.91% Upside176.41% Upside12.00% Upside
News Sentiment RatingPositive News
Neutral News
Neutral News
Community Rating
Outperform Votes
Underperform Votes
Avg. Outperform Votes
Avg. Underperform Votes
Avg. Outperform Votes
Avg. Underperform Votes

Editas Medicine (NASDAQ:EDIT) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/20/2021Robert W. Baird
Reiterated RatingBuy
10/19/2021SVB Leerink
R. Bienkowski
Initiated CoverageMarket Perform$41.00+7.11%
9/30/2021Chardan Capital
Geulah Livshits
Reiterated RatingBuy$75.00+81.25%
9/30/2021Stifel Nicolaus
Lower Price TargetHold$65.00 ➝ $46.00+8.24%
UpgradeMarket Perform ➝ Outperform$42.00 ➝ $80.00+24.15%
8/9/2021Truist Financial
Joon Lee
8/9/2021Truist Securities
UpgradeHold ➝ Buy$45.00 ➝ $80.00+43.91%
8/5/2021Evercore ISI
UpgradeUnderperform ➝ Outperform$20.00 ➝ $60.00+30.29%
5/10/2021Morgan Stanley
Lower Price TargetUnderweight$40.00 ➝ $37.00+8.47%
5/3/2021Royal Bank of Canada
Initiated CoverageSector Perform$40.00+12.52%
4/16/2021The Goldman Sachs Group
Initiated CoverageSell$20.00-51.20%
3/22/2021Credit Suisse Group
Initiated CoverageOutperform$58.00+28.89%
Reiterated RatingOverweight ➝ Equal Weight$46.00+10.50%
2/28/2021JPMorgan Chase & Co.
Reiterated RatingSell$30.00-31.60%
1/13/2021Wells Fargo & Company
Boost Price TargetOverweight$69.00 ➝ $86.00+14.67%
1/7/2021Raymond James
DowngradeOutperform ➝ Market Perform
6/18/2020SunTrust Banks
Initiated CoverageBuy$45.00+50.55%
2/7/2019BTIG Research
Initiated CoverageBuy$30.00+54.40%
Reiterated RatingBuy
(Data available from 11/28/2016 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Editas Medicine (NASDAQ:EDIT) Analyst Ratings Frequently Asked Questions

What is Editas Medicine's consensus rating and price target?

According to the issued ratings of 17 analysts in the last year, the consensus rating for Editas Medicine stock is Hold based on the current 3 sell ratings, 5 hold ratings and 9 buy ratings for EDIT. The average twelve-month price target for Editas Medicine is $57.27 with a high price target of $86.00 and a low price target of $20.00. Learn more on EDIT's analyst rating history

Do Wall Street analysts like Editas Medicine more than its competitors?

Analysts like Editas Medicine stock less than the stock of other Medical companies. The consensus rating for Editas Medicine is Hold while the average consensus rating for medical companies is Buy. Learn more on how EDIT compares to other companies

Do MarketBeat users like Editas Medicine more than its competitors?

MarketBeat users like Editas Medicine stock less than the stock of other Medical companies. 59.06% of MarketBeat users gave Editas Medicine an outperform vote while medical companies recieve an average of 67.43% outperform votes by MarketBeat users.

Is Editas Medicine being upgraded by Wall Street analysts?

Over the previous 90 days, Editas Medicine's stock had 1 upgrade by analysts.

Does Editas Medicine's stock price have much upside?

According to analysts, Editas Medicine's stock has a predicted upside of 19.61% based on their 12-month price targets.

What analysts cover Editas Medicine?

Editas Medicine has been rated by Chardan Capital, Oppenheimer, Robert W. Baird, Stifel Nicolaus, and SVB Leerink in the past 90 days.

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.